BioPoly was granted an additional European patent for its partial resurfacing implants. This newest patent addresses implant design; previous patents addressed materials.
BioPoly material combines polymer and hyaluronic acid into a “self-lubricated” polymer that can carry physiological loads without causing damage to other knee tissues, acting as a synthetic cartilage. The BioPoly® RS Partial Resurfacing Knee has been implanted successfully in Europe since 2012.
Last November, BioPoly received FDA approval to conduct an Investigational Device Exemption clinical study of its knee system. In 2016, it received CE Mark approval for use in the shoulder, followed in 2018 for repair of the trochlea.
BioPoly was granted an additional European patent for its partial resurfacing implants. This newest patent addresses implant design; previous patents addressed materials.
BioPoly material combines polymer and hyaluronic acid into a “self-lubricated” polymer that can carry physiological loads without causing damage to other knee tissues, acting...
BioPoly was granted an additional European patent for its partial resurfacing implants. This newest patent addresses implant design; previous patents addressed materials.
BioPoly material combines polymer and hyaluronic acid into a “self-lubricated” polymer that can carry physiological loads without causing damage to other knee tissues, acting as a synthetic cartilage. The BioPoly® RS Partial Resurfacing Knee has been implanted successfully in Europe since 2012.
Last November, BioPoly received FDA approval to conduct an Investigational Device Exemption clinical study of its knee system. In 2016, it received CE Mark approval for use in the shoulder, followed in 2018 for repair of the trochlea.
Copy to clipboard 
